DNA Read-Write-Edit Market Projected to Hit $67.7 Billion by 2030
A market research firm says the global DNA read, write, and edit industry will nearly double to $67.7 billion by 2030. Take the number with salt — but the underlying drivers are real enough to pay attention to.
Explanation
Market research reports love big numbers, and this one is no exception. The claim: the global market for reading (sequencing), writing (synthesis), and editing (think CRISPR) DNA will reach $67.7 billion by 2030, up from wherever it sits today, driven by three converging forces — more clinical uses, surging demand for genomic diagnostics, and heavy investment in CRISPR-based treatments.
Here's what's actually happening underneath the headline. DNA sequencing costs have collapsed over the past decade — whole-genome sequencing now costs under $200 in some settings, down from $3 billion for the first human genome in 2003. That price drop is pulling genomics out of research labs and into hospitals, cancer clinics, and newborn screening programs. More data means more demand for synthesis and editing tools to act on what's found.
CRISPR therapeutics are the flashiest piece. Casgevy, the first approved CRISPR drug (for sickle cell disease and beta-thalassemia), cleared the FDA and UK MHRA in late 2023. It's a proof-of-concept that gene editing can move from bench to bedside — and it opens the regulatory and commercial path for dozens of programs behind it.
Why care today? Because the infrastructure buildout — sequencing platforms, synthesis capacity, delivery systems for gene editors — is happening now. Companies positioning in reagents, instruments, and bioinformatics are the picks-and-shovels play regardless of which therapeutic bets win.
The $67.7 billion figure itself is a projection from an unnamed methodology, so treat it as directional, not precise. What would change the picture: a major clinical safety failure in CRISPR therapeutics, or a slowdown in reimbursement approvals for genomic diagnostics.
The $67.7 billion projection bundles three technically distinct market segments — next-generation sequencing (NGS) and long-read platforms, oligonucleotide and gene synthesis, and nuclease-based editing tools (CRISPR-Cas variants, TALENs, base editors, prime editors). Conflating them inflates the headline number and obscures where actual growth is concentrated.
The sequencing segment is the most mature and likely the largest contributor. Illumina still commands dominant share in short-read NGS, but competitive pressure from PacBio, Oxford Nanopore, and Element Biosciences is compressing margins while expanding total addressable volume. Long-read adoption is accelerating in structural variant detection and phased haplotyping — areas where short-read platforms structurally underperform.
On the editing side, Casgevy's dual approval (FDA November 2023, MHRA November 2023) is the sector's clearest clinical validation to date. The ex vivo HSC editing approach it uses, however, is capital- and logistics-intensive — limiting near-term scale. The more consequential medium-term question is whether in vivo delivery (LNP, AAV, or emerging non-viral vectors) can achieve tissue-specific editing efficiency at therapeutic doses without off-target accumulation. Base editing and prime editing programs from Beam Therapeutics, Prime Medicine, and others are attempting to answer that with higher precision profiles than canonical Cas9 DSB approaches.
Genomic diagnostics — liquid biopsy, pharmacogenomics, rare disease panels — represent the fastest path to revenue at scale because reimbursement infrastructure already exists in oncology. Guardant, Foundation Medicine, and Grail are expanding clinical utility claims, which directly drives sequencing reagent and instrument pull-through.
The synthesis market (Twist Bioscience, Integrated DNA Technologies, Evonetix) remains smaller but strategically critical: synthetic biology, mRNA therapeutics, and DNA data storage all depend on cost-per-base continuing to fall. Current electrochemical and photolithographic synthesis platforms are still orders of magnitude above the cost floor needed for commodity DNA storage.
Key falsifier for the bull case: a serious adverse event in a high-profile CRISPR trial would trigger regulatory tightening across the editing segment and compress multiples industry-wide. Watch FDA's evolving guidance on off-target assessment requirements — that's the near-term regulatory variable with the most market-moving potential.
Reality meter
Why this score?
Trust Layer Score basis
A detailed evidence breakdown is being added. For now, the score basis is the source list below and the reality meter above.
- 46 sources on file
- Avg trust 42/100
- Trust 40–95/100
Time horizon
Community read
Glossary
- next-generation sequencing (NGS)
- High-throughput DNA sequencing technology that can read millions of DNA fragments simultaneously, enabling rapid and cost-effective genome analysis. Modern NGS platforms like those from Illumina are foundational to genomics research and clinical diagnostics.
- long-read platforms
- Sequencing technologies that can read much longer stretches of DNA (thousands of bases) in a single read, enabling better detection of structural variants and phased haplotyping compared to short-read methods.
- CRISPR-Cas variants
- Gene-editing tools derived from bacterial immune systems that use guide RNAs to precisely cut DNA at targeted locations, allowing researchers to add, remove, or alter genetic material.
- ex vivo HSC editing
- A gene therapy approach where hematopoietic stem cells (blood-forming cells) are removed from a patient's body, edited outside the body to correct genetic defects, and then reinfused back into the patient.
- in vivo delivery
- The process of delivering therapeutic agents directly into a living organism's body to edit genes within tissues, using vectors like lipid nanoparticles (LNP) or adeno-associated viruses (AAV) to transport editing tools to target cells.
- off-target accumulation
- Unintended genetic edits or therapeutic agent buildup at locations in the genome other than the intended target site, which can cause harmful side effects.
- liquid biopsy
- A non-invasive diagnostic test that detects cancer or disease markers (such as circulating tumor DNA) from a blood sample, enabling early detection and monitoring without tissue biopsies.
What's your read?
Your read shapes future topic weighting.
Your vote feeds topic weights, community direction and future prioritisation. Open community direction
Sources
- Tier 3 Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications
- Tier 3 Biotechnology News -- ScienceDaily
- Tier 3 Colossal Biosciences announces ‘de-extinction’ plan for African bluebuck | CNN
- Tier 3 Clarkson University Researchers Contribute to Breakthrough Biosensor Technology Published in Nature Biotechnology | Clarkson University
- Tier 3 Biotech and Pharma Industry News | BioPharma Dive
- Tier 3 ScienceDaily: Your source for the latest research news
- Tier 3 Fierce Biotech News & Reports
- Tier 1 Nature Biotechnology
- Tier 3 2024 in science - Wikipedia
- Tier 3 Top Biotech Startups 2026: An Analysis of Emerging Trends | IntuitionLabs
- Tier 3 Study: CRISPR gene editing leads to improvements in vision for people with inherited blindness | Ophthalmology Times - Clinical Insights for Eye Specialists
- Tier 3 A one-time treatment tweaked their genes — and lowered their cholesterol
- Tier 3 Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics
- Tier 3 Potential Cure for HIV from CRISPR Gene Editing in Phase 1/2 Clinical Trial | Contagion Live
- Tier 3 Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
- Tier 3 CRISPR gene editing - Wikipedia
- Tier 3 Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder | BioPharma Dive
- Tier 3 Discovery broadens scope of use of CRISPR gene editing | ScienceDaily
- Tier 3 Scientists just made CRISPR three times more effective | ScienceDaily
- Tier 3 Synthetic Biology Market Size, Share, Industry Growth 2035
- Tier 3 Synthetic Biology Market Size, Share & Growth Trends 2035
- Tier 3 Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
- Tier 3 SynbiTECH 2026 | The Must-Attend Synthetic Biology Conference
- Tier 3 2026 Synthetic Biology: Engineering, Evolution, & Design (SEED) | AIChE
- Tier 3 Synthetic Biology Market worth $31.52 billion in 2029 | Press Releases | reformer.com
- Tier 3 Synthetic Biology Market Analysis 2026-2031: Genome Engineering Accounts for 33.21% Share, with Asia-Pacific as the Fastest-Growing Region, Says Mordor Intelligence
- Tier 3 North America Gene Synthesis Market Outlook 2026-2034
- Tier 3 Synthetic Biology Product Market is Going to Boom | Amyris , Zymergen
- Tier 3 List of Funded Biotech Startups (2026) - Fundraise Insider
- Tier 3 Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
- Tier 3 The Week’s 10 Biggest Funding Rounds: SiFive Leads With $400M For Custom Chip Designs As Aviation, Biotech And Defense Startups Also Raise Big
- Tier 3 1,200+ Funded Biotech Startups 2026 | Verified Contacts
- Tier 3 Biotech Valuation Benchmarks for Series A and B in 2026
- Tier 3 The Week’s 10 Biggest Funding Rounds: AI, Autonomy And Biotech Top The Ranks
- Tier 3 Biotechnology Startup Funding 2025-2026 – New Market Pitch
- Tier 3 Jeito Capital, prominent biotech investor, raises $1.2B for next fund | BioPharma Dive
- Tier 3 Stanford's James Zou targets $1B valuation for AI physiology startup backed by Nature-published research and FDA-cleared cardiac AI
- Tier 3 DNA origami vaccines could be the next leap beyond mRNA | ScienceDaily
- Tier 1 Engineered cells as programmable mRNA delivery vehicles | Nature Reviews Bioengineering
- Tier 3 AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet | BioPharm International
- Tier 3 New Research Challenges Understanding of mRNA Vaccines and Establishes Innovative Way to Make Them More Effective | Mount Sinai - New York
- Tier 3 mRNA Delivery Technology Landscape 2026 — PatSnap Eureka | PatSnap
- Tier 3 Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy | Cellular Oncology | Springer Nature Link
- Tier 3 After a year of turmoil, cancer researchers see promising signs for mRNA vaccines | CNN
- Tier 3 mRNA Therapeutics Market Size to Hit USD 83.49 Billion by 2035 - BioSpace
- Tier 3 Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy - PMC
Optional Submit a prediction Optional: add your prediction on the core question if you like.
Prediction
Will at least three additional CRISPR-based therapeutics receive regulatory approval (FDA or EMA) by the end of 2027?